Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| H9H-MC-JBAU | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants in this study will receive two oral doses of 150 milligram (mg) LY2157299 taken at least 4 days apart. One dose will be given without food. One dose will be given with a high fat meal. The study will evaluate the effect of a high fat meal on how much of the drug gets into the blood stream. Side effects will be documented. This study will last approximately 15 days not including screening. Screening is required within 30 days prior to the start of the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LY2157299 (Fasted) | Experimental | Single dose of 150 mg LY2157299 administered orally in fasted state in one of two study periods. |
|
| LY2157299 (Fed) | Experimental | Single dose of 150 mg LY2157299 administered orally in fed state in one of two study periods. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LY2157299 | Drug | Administered orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of LY2157299 | Pre-dose through 72 hours post-dose in each study period | |
| Pharmacokinetics: Time of Maximum Observed Concentration (tmax) of LY2157299 | Pre-dose through 72 hours post-dose in each study period | |
| Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2157299 | Pre-dose through 72 hours post-dose in each study period |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Daytona Beach | Florida | 31227 |
Not provided
| ID | Term |
|---|---|
| C557799 | LY-2157299 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| United States |